Clinical determinants of successful weaning from extracorporeal membrane oxygenation in patients with fulminant myocarditis

Patients with fulminant myocarditis (FM) often present with cardiogenic shock and require mechanical circulatory support, including extracorporeal membrane oxygenation (ECMO) and ventricular assist device (VAD) implantation. This study sought to clarify the determinants of successful weaning from ECMO in FM patients.

[1]  F. Pappalardo,et al.  Treating Life-Threatening Myocarditis by Blocking Interleukin-1* , 2016, Critical care medicine.

[2]  O. Alfieri,et al.  Venoarterial Extracorporeal Membrane Oxygenation for Acute Fulminant Myocarditis in Adult Patients: A 5-Year Multi-Institutional Experience. , 2016, The Annals of thoracic surgery.

[3]  Michael Bailey,et al.  Predicting survival after ECMO for refractory cardiogenic shock: the survival after veno-arterial-ECMO (SAVE)-score. , 2015, European heart journal.

[4]  J. Goldstein,et al.  2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care: Endorsed by the American Heart Assocation, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion; Affirmation o , 2015, Journal of the American College of Cardiology.

[5]  J. Goldstein,et al.  2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care: Endorsed by the American Heart Association, the Cardiological Society of India, and Sociedad Latino Americana de Cardiología Intervencionista; Affirmat , 2015, Journal of the American College of Cardiology.

[6]  R. Thiagarajan,et al.  Extracorporeal Membrane Oxygenation for the Support of Adults With Acute Myocarditis , 2015, Critical care medicine.

[7]  Minoru Ono,et al.  The registry report of heart transplantation in Japan (1999-2013). , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[8]  R. Cheng,et al.  Clinical outcomes in fulminant myocarditis requiring extracorporeal membrane oxygenation: a weighted meta-analysis of 170 patients. , 2014, Journal of cardiac failure.

[9]  E. Walsh,et al.  In-hospital arrhythmia development and outcomes in pediatric patients with acute myocarditis. , 2013, The American journal of cardiology.

[10]  G. Barbati,et al.  Long-Term Evolution and Prognostic Stratification of Biopsy-Proven Active Myocarditis , 2013, Circulation.

[11]  M. Acker,et al.  Rapid onset of fulminant myocarditis portends a favourable prognosis and the ability to bridge mechanical circulatory support to recovery. , 2013, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[12]  S. Miyagawa,et al.  Initial experience of conversion of Toyobo paracorporeal left ventricular assist device to DuraHeart left ventricular assist device. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[13]  N. Chi,et al.  Extracorporeal membranous oxygenation support for acute fulminant myocarditis: analysis of a single center's experience. , 2011, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[14]  D. Mancini,et al.  Selection of Cardiac Transplantation Candidates in 2010 , 2010, Circulation.

[15]  H. Ichikawa,et al.  Fifteen-year experience with Toyobo paracorporeal left ventricular assist system , 2009, Journal of Artificial Organs.

[16]  T. Takayama,et al.  Mechanical circulatory support for fulminant myocarditis , 2008, Surgery Today.

[17]  B. McManus,et al.  Molecular biology and pathogenesis of viral myocarditis. , 2008, Annual review of pathology.

[18]  S. Yasuda,et al.  Favourable clinical outcome in patients with cardiogenic shock due to fulminant myocarditis supported by percutaneous extracorporeal membrane oxygenation. , 2005, European heart journal.

[19]  I. Takeuchi,et al.  Serum levels of interleukin-10 on admission as a prognostic predictor of human fulminant myocarditis. , 2004, Journal of the American College of Cardiology.

[20]  M. Acker.  Mechanical circulatory support for patients with acute-fulminant myocarditis. , 2001, The Annals of thoracic surgery.

[21]  T. Aiba,et al.  Appropriate indications for the use of a percutaneous cardiopulmonary support system in cases with cardiogenic shock complicating acute myocardial infarction. , 2001, Japanese circulation journal.

[22]  R. Hruban,et al.  Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. , 2000, The New England journal of medicine.

[23]  Y. Taenaka,et al.  Practical assessment of natural heart function using echocardiography in mechanically assisted patients. , 1991, ASAIO transactions.

[24]  H. Aretz.  Myocarditis: the Dallas criteria. , 1987, Human pathology.

[25]  Fredric Ginsberg,et al.  Fulminant myocarditis. , 2013, Critical care clinics.

[26]  A. Pavie,et al.  Paracorporeal pulsatile biventricular assist device versus extracorporal membrane oxygenation-extracorporal life support in adult fulminant myocarditis. , 2009, The Journal of thoracic and cardiovascular surgery.

[27]  Shu-Chien Huang,et al.  Experience and result of extracorporeal membrane oxygenation in treating fulminant myocarditis with shock: what mechanical support should be considered first? , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[28]  S. Colan,et al.  Gamma-globulin treatment of acute myocarditis in the pediatric population. , 1994, Circulation.